Philip Raskin

25.5k citations

272 papers · 16.7k indexed · 5 hit papers · h-index 65

Impact in

Endocrinology, Diabetes and Metabolism top 0.02%
- Diabetes Management and Research
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
Nephrology top 0.5%

Papers in

Endocrinology, Diabetes and Metabolism 170
- Diabetes Management and Research 100
- Diabetes Treatment and Management 79
- Diabetes, Cardiovascular Risks, and Lipoproteins 27
Clinical Biochemistry 12

Co-authors: Roger H. Unger Julio Rosenstock Suzanne Strowig A Pietri Beverley Adams‐Huet Sherwyn Schwartz Larissa Avilés‐Santa Jennifer B. Marks
Journals: Diabetes Care (35 papers)Journal of Diabetes and its Complications (27 papers)Diabetes (24 papers)The American Journal of Medicine (12 papers)Diabetes Obesity and Metabolism (12 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Philip Raskin

266 papers receiving 15.6k citations

Hit Papers

5 papers align trajectories log scale

Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes 2011 · 707 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2011 New England Journal of Medicine
2011 The Lancet
2009 New England Journal of Medicine
2009 Diabetes Care
2004 JAMA

Peers

Countries citing papers authored by Philip Raskin

Since Specialization

Citations

This map shows the geographic impact of Philip Raskin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Raskin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Raskin more than expected).

Fields of papers citing papers by Philip Raskin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Raskin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Raskin. The network helps show where Philip Raskin may publish in the future.

Co-authors

The 25 scholars most cited alongside Philip Raskin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philip Raskin Line = papers co-authored together Philip Raskin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Retinopathy During the First 5 Years of Type 1 Diabetes and Subsequent Risk of Advanced Retinopathy Diabetes Care ·John I. Malone, Xiaoyu Gao, Gayle M. Lorenzi, Philip Raskin, Neil H. White, Dean P. Hainsworth, Arup Das, William V. Tamborlane, Amisha Wallia, Lloyd Paul Aiello, Ionut Bebu	2022	2
2	Shape of the OGTT glucose response curve: relationship with β-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin BMJ Open Diabetes Research & Care ·Kristina M. Utzschneider, Naji Younes, Neda Rasouli, Joshua I. Barzilay, Mary Ann Banerji, Robert M. Cohen, Erica Gonzalez, Faramarz Ismail‐Beigi, Kieren J. Mather, Philip Raskin, Deborah J. Wexler, John M. Lachin, Steven E. Kahn	2021	19
3	Comparison of a Novel Insulin Bolus-Patch with Pen/Syringe Injection to Deliver Mealtime Insulin for Efficacy, Preference, and Quality of Life in Adults with Diabetes: A Randomized, Crossover, Multicenter Study Diabetes Technology & Therapeutics ·Nancy J.V. Bohannon, Richard M. Bergenstal, Robert Cuddihy, Davida Kruger, S List, Elaine Massaro, Mark E. Molitch, Philip Raskin, Heather Remtema, Suzanne Strowig, Fred W. Whitehouse, Rocco L. Brunelle, Darlene M. Dreon, Meng H. Tan	2011	16
4	Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial The Lancet ·Diane K. Wherrett, Brian N. Bundy, Dorothy J. Becker, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Carla J. Greenbaum, Kevan C. Herold, Jennifer B. Marks, Roshanak Monzavi, Antoinette Moran, Tihamer Orban, Jerry P. Palmer, Philip Raskin, Henry Rodriguez, Desmond Schatz, Darrell M. Wilson, Jeffrey P. Krischer, Jay S. Skyler	2011	274
5	Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230)) Diabetes Care ·Bernard Zinman, J. E. Gerich, John B. Buse, Alex Lewin, S. Schwartz, Philip Raskin, Paula M. Hale, Marija Zdravković, Lawrence Blonde	2010	240
6	A Comparison of Twice-Daily Biphasic Insulin Aspart 70/30 and Once-Daily Insulin Glargine in Persons With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Therapy: A Randomized, Open-Label Study Endocrine Practice ·Robert J. Ligthelm, Titus Gylvin, Tony DeLuzio, Philip Raskin	2010	22
7	β‐Blocker use and diabetes symptom score: results from the GEMINI study Diabetes Obesity and Metabolism ·Janet B. McGill, George L. Bakris, Vivian Fonseca, Philip Raskin, Franz H. Messerli, Robert A. Phillips, Richard E. Katholi, Jackson T. Wright, Malini Iyengar, Karen M. Anderson, Mary Ann Lukas, Mehul Dalal, David S.H. Bell	2007	20
8	Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes Journal of Diabetes and its Complications ·Ildiko Lingvay, Philip Raskin, Lidia S. Szczepaniak	2007	40
9	The diabetic lung: Relevance of alveolar microangiopathy for the use of inhaled insulin The American Journal of Medicine ·Connie C. W. Hsia, Philip Raskin	2005	68
10	A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes Diabetes Care ·Philip Raskin, Marc Rendell, Matthew C. Riddle, Jo Dole, Martin I. Freed, Julio Rosenstock	2001	268
11	Diabetic Foot Tendinopathy Journal of Diabetes and its Complications ·Luis C. Ramirez, Philip Raskin	1998	22
12	HYPERTENSION IN DIABETES MELLITUS Endocrinology and Metabolism Clinics of North America ·Carlos Arauz-Pacheco, Philip Raskin	1996	10
13	Glycemic control and the complications of diabetes: Afer the diabetes control and complications trial Suzanne Strowig, Philip Raskin	1995	22
14	Relationship between diabetes control and pulmonary function in insulin-dependent diabetes mellitus The American Journal of Medicine ·Luis C. Ramirez, Anthony Dal Nogare, Connie C. W. Hsia, Carlos Arauz, Irfan Butt, Suzanne Strowig, Laura Schnurr-Breen, Philip Raskin	1991	55
15	The hypercalciuria of diabetes mellitus: Its amelioration with insulin Diabetes ·Philip Raskin, MURIEL R. M. STEVENSON, D. E. Barilla, Charles Y.C. Pak	1978	3
16	Somatostatin-like immunoreactivity in human plasma Clinical research ·J. Michael Conlon, Valerie Harris, Philip Raskin	1978	3
17	Role of insulin lack in the abnormal glucagon (IRG) response in human diabetes Clinical research ·İbrahim Aydın, Philip Raskin, Roger H. Unger	1977	1
18	Increased plasma immunoreactive somatostatin (IRS) levels in alloxan diabetic dogs and juvenile diabetic humans Diabetologia ·V. Schusdziarra, Richard Dobbs, Philip Raskin, Roger H. Unger	1977	1
19	Effect of insulin and somatostatin on A cell dysfunction in human diabetes Clinical research ·Philip Raskin, Roger H. Unger	1976	1
20	Effects of exogenous glucagon in insulin treated diabetics Diabetes ·Philip Raskin, Roger H. Unger	1976	2

About Philip Raskin

Philip Raskin is a scholar working on Endocrinology, Diabetes and Metabolism, Clinical Biochemistry, Cardiology and Cardiovascular Medicine, Pharmacology and Nephrology, having authored 272 papers that have together received 16.7k indexed citations. Recurring topics across this work include Diabetes Management and Research (100 papers), Diabetes Treatment and Management (79 papers), Pancreatic function and diabetes (47 papers), Metabolism, Diabetes, and Cancer (43 papers), Diabetes and associated disorders (40 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (27 papers), Pharmacology and Obesity Treatment (24 papers) and Blood Pressure and Hypertension Studies (19 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (9.8k citations), Nephrology (941 citations), Genetics (3.4k citations), Cardiology and Cardiovascular Medicine (2.5k citations) and Surgery (4.7k citations). Philip Raskin has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Roger H. Unger, Julio Rosenstock, Suzanne Strowig, A Pietri, Beverley Adams‐Huet, Sherwyn Schwartz, Larissa Avilés‐Santa, Jennifer B. Marks, Jay S. Skyler and Andrew Lewin. Their work appears in journals such as Diabetes Care, Journal of Diabetes and its Complications, Diabetes, The American Journal of Medicine and Diabetes Obesity and Metabolism.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact